MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,162.60 +26.23 (+2.31%)
Streaming Delayed Price Updated: 2:13 PM EDT, Jun 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
3 of Wall Street’s Favorite Stocks We Think Twice About
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember... 
Via StockStory
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
DRAM Memory Boom: Why Micron Stock Could Still Double ↗
Micron's share price doubled in 48 days. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
5 Best Growth Stocks for the Next 10 Years ↗
These 5 long-term growth stocks could benefit from AI, cybersecurity, GLP-1 drugs, and fintech trends over the next decade 
Via MarketBeat
Topics Artificial Intelligence Economy
News headline image
Prediction: After Micron and AMD, This Will Be the Next Tech Stock to Join the $1 Trillion Club ↗
ASML's lithography machines are needed to manufacture advanced AI processing and memory chips. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Lilly's New Drug Just Delivered the Largest Weight Loss Ever Seen in a Clinical Trial -- Here's What It Means for Investors ↗
Eli Lilly is working on a new GLP-1 drug, and early results suggest it could be a big winner. 
Via The Motley Fool
News headline image
The Smartest Growth Stocks to Buy With $2,000 Right Now ↗
Most of the market's best-known growth names are overbought at this time. That's not the case for several off-the-radar alternatives. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Stock Split Watch: Is Eli Lilly Next? ↗
Lilly has split its stock in the past. 
Via The Motley Fool
News headline image
Stock Market Today, May 28: Tech Stocks Rise as Snowflake Surges After $6 Billion Amazon Deal and Strong Earnings ↗
Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged. 
Via The Motley Fool
Topics Artificial Intelligence Earnings Economy
News headline image
Why Eli Lilly (LLY) Stock Is Trading Up Today
What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferre... 
Via StockStory
News headline image
Why Is Eli Lilly Stock Surging On Thursday? ↗
Eli Lilly (NYSE:LLY) shares jumped on Thursday morning after securing expanded PBM coverage for its blockbuster obesity treatments, Zepbound and Foundayo. 
Via Benzinga
News headline image
Contrarian Opinion: Novo Nordisk Is A Better Buy Than Eli Lilly Right Now ↗
Novo Nordisk lost its lead in the GLP-1 race, but Eli Lilly's valuation is a bit rich. 
Via The Motley Fool
News headline image
Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? ↗
Hims & Hers is acquiring Australian telehealth platform Eucalyptus as part of its international expansion plan while using $350 million in convertible senior notes. 
Via MarketBeat
Topics Earnings
News headline image
VHT vs. XBI: Vanguard Health Care ETF Tops SPDR Biotech in Yield and Cost ↗
Expense ratios, yield, and sector breadth set these healthcare ETFs apart—see how their risk profiles and portfolio strategies compare. 
Via The Motley Fool
Topics ETFs
News headline image
Is Eli Lilly Stock Outperforming the Nasdaq?
Eli Lilly has outpaced the Nasdaq Composite over the past year, and analysts remain very confident in its longer-term trajectory. 
Via Barchart.com
Topics Stocks
News headline image
Is Johnson & Johnson Stock Outperforming the Dow?
Johnson & Johnson has outperformed the Dow Jones over the past year, and analysts remain moderately optimistic about the stock’s outlook. 
Via Barchart.com
Topics Stocks
News headline image
5 Undervalued Stocks You Can Buy and Hold Forever ↗
Buying and holding stocks is an excellent strategy to increase your wealth. 
Via The Motley Fool
News headline image
3 Healthcare Stocks We Keep Off Our Radar
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recentl... 
Via StockStory
News headline image
2 Mega-Cap Stocks on Our Buy List and 1 We Find Risky
Megacap stocks dominate their sectors and their actions influence economies worldwide. The flip side though is that their sheer size means they have less roo... 
Via StockStory
News headline image
Novo Nordisk Is Beating Eli Lilly in the Obesity Pill Market. Should Lilly Investors Be Worried? ↗
There is no reason to panic just yet. 
Via The Motley Fool
News headline image
President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too? ↗
Eli Lilly's fundamentals matter more than Trump's stock purchases. 
Via The Motley Fool
Topics Government
News headline image
The $4 Billion Reason Eli Lilly Stock Is Up Today
Eli Lilly shares inch higher as the company announced three acquisitions for nearly $4 billion. Here’s why each of the three vaccine makers it’s buying is bullish for LLY stock. 
Via Barchart.com
News headline image
GLP-1 Drugs Powered IHE's Big Year. IXJ Is Playing a Longer Game. ↗
A closer look at portfolio makeup, yield, and risk reveals what sets these two iShares healthcare funds apart for investors seeking sector exposure. 
Via The Motley Fool
Topics ETFs
News headline image
PPH vs. IXJ: A Pure Pharma Bet Against the Entire Global Healthcare Ecosystem ↗
A concentrated pharma focus sets VanEck apart from iShares’ broader healthcare approach. See how portfolio differences shape risk and income profiles. 
Via The Motley Fool
Topics ETFs
News headline image
Micron Just Became America's 10th-Most-Valuable Company. Wall Street Says It Could Pass Tesla and Meta Next. ↗
Surging demand for the memory chipmaker's AI products has sent its stock soaring. But a rally this steep doesn't come without risk. 
Via The Motley Fool
Topics Artificial Intelligence Earnings
News headline image
Is Eli Lilly Stock an Undervalued Stock to Buy? ↗
Consumer demand for Eli Lilly's weight-loss treatments continues to rise. 
Via The Motley Fool
News headline image
Investment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC Filing ↗
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
From Shingles To Superbugs: Eli Lilly Expands Infectious Disease Push In Billion-Dollar Buying Wave ↗
Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention. 
Via Benzinga
News headline image
Ozempic, Other Weight Drug Users Cut Back On Eating Out. What That Means For Restaurants. ↗
For some types of restaurants, the damage is bigger. 
Via Investor's Business Daily
News headline image
Eli Lilly Goes On A $3.83 Billion Acquisition Spree. Where's It Pushing Now? ↗
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story